Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for maintenance of electrolyte balance; dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolarity.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion; rate and volume determined by electrolyte needs and fluid status; typical maintenance: 0.9% sodium chloride with 20 mEq/L potassium chloride at 125 mL/hour; potassium chloride 0.3% provides 40 mEq/L, dextrose 5% and sodium chloride 0.11% provides 19 mEq/L sodium; consult institutional protocols.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 2-4 hours for potassium ions, reflecting rapid renal clearance but can be prolonged in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal (90% as potassium ions), with minor fecal (10%) and negligible biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte